Curanex Pharmaceuticals Inc. (NASDAQ:CURX) on Wednesday highlighted five additional patient cases that management believes further support the potential of its lead candidate, Phyto-N, in cancer cachexia.

Patient Cases Suggest Functional Recovery Trends

The company highlighted five additional patient accounts involving advanced cancers and end-stage conditions, where individuals reported improvements in appetite, mobility, and overall physical condition after using its product.

These cases follow a previously disclosed patient experience that management viewed as an early signal of potential relevance in cachexia—a condition marked by weight loss, muscle wasting, and declining functional capacity.

The first patient case showed that after initiating treatment with Phyto-N, the patient reported notable improvements within about a month.

These included increased energy levels, reduced abdominal pain, and normalization of urinary patterns.

Across the newly cited cases, patients with advanced thymic carcinoma, small cell lung cancer, pancreatic cancer complications, liver cirrhosis, and end-stage renal disease described regaining strength, resuming normal eating, and improving mobility.

Several accounts also noted extended survival timelines relative to initial clinical expectations.

Curanex Broad Themes Across Severe Disease Settings

In multiple instances, patients reported regaining the ability to walk, eat, and perform daily activities.

The company believes such functional improvements are particularly relevant in supportive oncology, where maintaining physical condition can influence both quality of life and treatment continuity.

Jun Liu, the company's CEO, said the recurring themes across diverse conditions suggest the therapy may have broader applicability in helping patients rebuild physical resilience.

Strategic Focus On Curanex Cachexia Opportunity

Curanex has expanded its development focus to include cancer cachexia, which it views as a major unmet need with no approved therapies in the U.S. specifically targeting the condition.

The company said any therapy that helps patients maintain weight, strength, or treatment eligibility could have meaningful clinical and commercial value.

Company Urges Caution On Interpretation

Curanex emphasized that the reported cases are anecdotal and observational, and do not establish safety or efficacy.

However, management said the consistency of reported outcomes across multiple severe cases may help guide future research and development priorities in cachexia and related conditions involving systemic decline.

CURX Stock Price Activity: Curanex shares were up 2.06% at $0.44 during premarket trading on Wednesday, according to Benzinga Pro data.

Image via Shutterstock